Introduction
============

Indolizidine alkaloids are an important class of naturally occurring compounds which have received considerable attention as a result of their valuable physiological properties. A number of representatives of this class exhibit glycosidase inhibitory activity or antimetastatic, anticancer, antitumour or anti-HIV properties \[[@R1]--[@R3]\]. A large number of natural products contain an indolizidine framework, among them (−)-δ-coniceine, (−)-swainsonine, indolizidine 167B \[[@R4]--[@R10]\], (+)-lentiginosine \[[@R11]--[@R15]\], (+)-slaframine \[[@R16]\], (−)-elaeokanine C \[[@R17]\], (+)-cyclizidine \[[@R18]\], lepadiformine \[[@R19]\], the highly oxygenated (+)-castanospermine \[[@R20]--[@R21]\], or pumiliotoxin \[[@R22]\]. [Fig. 1](#F1){ref-type="fig"} illustrates the structures of several such compounds.

![Some indolizidine alkaloids.](Beilstein_J_Org_Chem-11-596-g002){#F1}

Tashiromine is a natural indolizidine alkaloid isolated from *Maackia tashiroi* (1990). Strategies for the synthesis of indolizidine derivatives have received considerable interest from synthetic and medicinal chemists ([Fig. 2](#F2){ref-type="fig"}). A number of synthetic approaches have been described earlier for construction of the indolizidine framework; access to tashiromine in racemic form can be achieved through the alkylation of succinimide, followed by ring closure via acyliminium intermediates \[[@R23]--[@R24]\], the reduction of cyclized pyridinium salts \[[@R25]\], iminium cascade cyclization \[[@R26]\], alkyne-mediated hydroformylation--cyclization \[[@R27]\], or electrophilic pyrolidinone alkylation followed by ring closure \[[@R28]--[@R29]\]. Pyrrolidine alkylation and nucleophilic ring closure followed by C--C double bond hydroboration \[[@R30]\] leads to racemic epitashiromine, as does the *N*-alkylated succinimide transformation through the corresponding indolizidinone \[[@R31]\].

![Approaches to racemic tashiromine and epitashiromine.](Beilstein_J_Org_Chem-11-596-g003){#F2}

Several synthetic procedures have also been developed for the preparation of tashiromine or epitashiromine enantiomers.

(+)-Tashiromine has been synthetized from a pyrrolidinone derivative through chiral Lewis acid-catalysed cyclization to substituted pyrrolidinones \[[@R17]\], by the intramolecular cyclization of a chiral alkenylated pyrrolidinone, followed by hydroxylation \[[@R32]\], or by the intramolecular ring closure of chiral pyrrolidine diesters followed by ester and oxo group reduction \[[@R33]\], while the syntheses of (+)-epitashiromine starts from a chiral morpholine derivative, with nitrone 1,3-dipolar cycloaddition and reduction \[[@R34]\] ([Fig. 3](#F3){ref-type="fig"}).

![Synthetic routes to (+)-tashiromine and (+)-epitashiromine.](Beilstein_J_Org_Chem-11-596-g004){#F3}

(−)-Tashiromine has been accessed through the ring closure of difunctionalized acyclic chiral sulfonamide-based β-amino acids \[[@R35]\], the cyclization of pyrrole derivatives with a chiral side-chain \[[@R36]\], or the enantioselective arylation of pyrrole, followed by saturation \[[@R37]\]. The transformation of chiral functionalized pyrrole or pyrrolidine derivatives has served as the basis of the construction of (−)-epitashiromine \[[@R38]--[@R39]\] ([Fig. 4](#F4){ref-type="fig"}).

![Synthetic routes to (−)-tashiromine and (−)-epitashiromine.](Beilstein_J_Org_Chem-11-596-g005){#F4}

The oxidative functionalization of cyclic β-amino acid derivatives has been reported to be a convenient route for the preparation of *N*-heterocyclic β-amino acid derivatives \[[@R40]--[@R41]\] or for the stereocontrolled synthesis of functionalized cispentacins \[[@R42]\] and their acyclic counterparts \[[@R43]--[@R44]\] ([Fig. 5](#F5){ref-type="fig"}). The oxidative ring cleavage of various vicinal diols and the transformation of the resulting dialdehyde intermediates has been efficiently applied in recent years for the synthesis of a series of valuable organic molecules \[[@R45]--[@R52]\]. In particular, Davies and co-workers have utilized the oxidative ring opening of cyclic vicinal diols followed by ring closure for access to pyrrolizidine alkaloids \[[@R45]\].

![Oxidative functionalizations of cyclic β-amino acids.](Beilstein_J_Org_Chem-11-596-g006){#F5}

Results and Discussion
======================

We describe here a novel access route for the synthesis of tashiromine and epitashiromine by starting from an unsaturated bicyclic β-lactam. The retrosynthetic concept of the synthesis is represented on [Scheme 1](#C1){ref-type="fig"} and was based on the lactam ring opening, in continuation followed by oxidative ring opening of the formed β-amino esters and by reductive ring closure as key steps.

![Retrosynthesis of tashiromine and epitashiromine.](Beilstein_J_Org_Chem-11-596-g007){#C1}

Bicyclic β-lactam (±)-**1** \[[@R53]--[@R54]\] was first transformed by azetidinone opening to the corresponding amino ester hydrochloride (±)-**2** \[[@R53]--[@R54]\], *N*-protection of which with benzyl chloroformate (Z-Cl) afforded protected amino ester (±)-**3** in 78% yield. In agreement with our earlier observations \[[@R40]--[@R42]\] C--C double bond functionalization of the cyclooctene β-amino ester via dihydroxylation with *N*-methyl morpholine *N*-oxide (NMO) in the presence of OsO~4~ afforded the corresponding *all-cis* dihydroxylated ethyl β-aminocyclooctanecarboxylate (±)-**4** in 90% yield (for dihydroxylation, see also reference \[[@R54]\]) ([Scheme 2](#C2){ref-type="fig"}). Amino ester (±)-**4** was next subjected through its vicinal diol moiety to oxidative ring opening with NaIO~4~ in MeOH at 20 °C, which resulted (monitored by TLC) in the corresponding ring-opened unstable diformyl intermediate (**I1**), which after work-up was immediately used without further purification (for several similar types of acyclic diformyl intermediates, see references \[[@R40]--[@R41] [@R43]--[@R44]\]). Thus, the crude material was submitted to catalytic hydrogenolysis and after *N*-deprotection underwent double cyclization--reduction to furnish indolizidine ester (±)-**5** in 41% yield after purification by chromatography.

![Synthesis of (±)-tashiromine ((±)-**6**).](Beilstein_J_Org_Chem-11-596-g008){#C2}

Reduction of the ester group of (±)-**5** with an excess of LiAlH~4~ in THF at 20 °C gave the corresponding tashiromine (±)-**6** \[[@R35]--[@R37]\], which was isolated in 48% yield after purification by column chromatography ([Scheme 2](#C2){ref-type="fig"}). The stereochemistry of (±)-**6** was unequivocally assigned by NMR data, which were consistent with those reported \[[@R35]--[@R37]\].

A similar strategy was applied for the synthesis of epitashiromine. On reaction with NaOEt in EtOH at 20 °C, ethyl *cis*-β-aminocyclooctenecarboxylate (±)-**3** underwent epimerization at C-1, leading after 18 h to an equilibrium mixture of *cis* and *trans* amino esters (1:1 ratio determined by ^1^H NMR on the crude mixture), the required *trans* isomer (±)-**7** being separated from the *cis* counterpart and isolated in a yield of 48% by means of column chromatography. Dihydroxylation of (±)-**7** with NMO/OsO~4~ next afforded an oily mixture of *cis* and *trans* dihydroxylated cyclooctane β-amino esters (diastereomeric mixture of (±)-**8**) in 77% overall yield after column chromatography. Our attempts to separate this nearly 1:1 mixture of the two dihydroxylated stereoisomers (determined on the basis of ^1^H NMR data) failed, but the mixture could be applied in the next ring-opening oxidation step, since it gave only one open-chain diformyl intermediate **I2**.

Similarly to the *cis* isomer, this unstable dialdehyde intermediate was subjected without isolation to catalytic hydrogenolysis, followed by reductive cyclization, to give the corresponding indolizidine ester (±)-**9** in 40% yield. Finally, ester reduction with LiAlH~4~ in THF resulted in epitashiromine (±)-**10** \[[@R32],[@R34],[@R39]\] in 53% yield after isolation by chromatography ([Scheme 3](#C3){ref-type="fig"}). The stereochemistry of (±)-epitashiromine was assigned by NMR data, which were in agreement with those reported \[[@R32],[@R34],[@R39]\].

![Synthesis of (±)-epitashiromine ((±)-**10**).](Beilstein_J_Org_Chem-11-596-g009){#C3}

Conclusion
==========

In summary, a novel stereocontrolled efficient method has been presented for the synthesis of tashiromine and epitashiromine alkaloids in six or seven steps, based on the preparation of *cis* or *trans* cyclooctene β-amino esters, followed by their oxidative ring cleavage and double reductive ring-closure reactions.

Experimental
============

General procedure for the Z-protection of amino esters
------------------------------------------------------

To a solution of amino ester hydrochloride ((±)-**2** or (−)-**2**) \[[@R29]\] (17.8 mmol) in THF (40 mL), Et~3~N (9 mL) was added at 0 °C, followed by 7.8 mL (1 equivalent) of Z-Cl (a 50% solution in toluene). The mixture was stirred for 14 h at 20 °C, and then was diluted with EtOAc (120 mL). The organic layer was washed with H~2~O (3 × 60 mL), dried (Na~2~SO~4~), and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (*n*-hexane/EtOAc 4:1), affording the amino ester.

General procedure for the dihydroxylation of amino esters
---------------------------------------------------------

To a solution of *cis* or *trans* Z-protected amino ester ((±)-**3**, (−)-**3** or (±)-**7**) (2.9 mmol) in acetone (30 mL) and H~2~O (1 mL), NMO (1.5 equivalents) and 2% OsO~4~ in *t*-BuOH (0.7 mL) were added and the mixture was stirred at 20 °C for 4 h. A saturated aqueous solution of Na~2~SO~3~ (40 mL) was then added, the mixture was extracted with CH~2~Cl~2~ (3 × 30 mL), and the organic layer was dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (*n*-hexane/EtOAc 1:4) to give the dihydroxylated amino ester.

General procedure for epimerization of the *cis*-amino ester
------------------------------------------------------------

To a solution of *cis N*-protected amino ester ((±)-**3** or (−)-**3**) (3.3 mmol) in EtOH (30 mL), EtONa (1.5 equivalents) was added at 0 °C and the mixture was stirred at 20 °C for 18 h. H~2~O (70 mL) was then added, the mixture was extracted with CH~2~Cl~2~ (3 × 30 mL), and the organic layer was dried over Na~2~SO~4~ and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (*n*-hexane/EtOAc 9:1) to give the *trans* isomer as a colourless oil.

General procedure for the oxidative ring opening/reductive ring closure of dihydroxylated amino esters
------------------------------------------------------------------------------------------------------

To a solution of dihydroxylated amino ester ((±)-**4**, (±)-**8** or (−)-**8**) (2.46 mmol) in MeOH (25 mL), NaIO~4~ (2 equivalents) was added and the mixture was stirred at 20 °C for 45 min. It was then diluted with H~2~O (50 mL) and extracted with CH~2~Cl~2~ (3 × 20 mL). The organic layer was dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude mixture was dissolved in EtOAc (30 mL), Pd/C (150 mg) was added and the mixture was stirred at 20 °C for 16 h. The catalyst was next filtered off through Celite. The crude mixture was then purified by column chromatography on silica gel (CH~2~Cl~2~/MeOH 95:5 or CH~2~Cl~2~/MeOH 9:1) to give the indolizidine derivative.

General procedure for reduction of the ester
--------------------------------------------

To a solution of indolizidine carboxylate ((±)-**5**, (±)-**9** or (−)-**9**) (1 mmol) in dry THF (15 mL), LiAlH~4~ (5 equivalents) was added at 0 °C and the mixture was stirred at 20 °C for 4 h. It was then cooled to 0 °C, H~2~O (2 mL) was added dropwise and the solid formed was filtered off through Celite. The filtrate was extracted with CH~2~Cl~2~ (3 × 15 mL), and the combined organic layers were dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude oil was purified by column chromatography on silica gel (CH~2~Cl~2~/MeOH/NH~4~OH 90:8:2 or CH~2~Cl~2~/MeOH/NH~4~OH 90:5:5) to give the alkaloid.

**Ethyl (1** ***R*** **\*,2** ***S*** **\*)-2-(benzyloxycarbonylamino)cyclooct-5-enecarboxylate ((±)-3)**

![](Beilstein_J_Org_Chem-11-596-i001.jpg)

A colourless oil (*R* ~f~ 0.6, *n*-hexane/EtOAc 4:1); yield: 78%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.28 (t, *J* = 7.1 Hz, 3H, CH~3~), 1.76--1.87 (m, 2H, CH~2~), 1.88--1.97 (m, 1H, CH~2~), 1.98--2.07 (m, 1H, CH~2~), 2.09--2.18 (m, 2H, CH~2~), 2.22--2.31 (m, 1H, CH~2~), 2.43--2.52 (m, 1H, CH~2~), 2.82--2.89 (m, 1H, H-1), 4.12--4.21 (m, 2H, OCH~2~), 4.22--4.30 (m, 1H, H-2), 5.08 (s, 2H, OCH~2~), 5.30 (brs, 1H, N-H), 5.60--5.74 (m, 2H, H-5 and H-6), 7.33--7.48 (m, 5H, Ar-H); ^13^C NMR (100 MHz, DMSO) δ 14.9, 24.4, 25.1, 26.6, 32.3, 46.4, 52.1, 60.6, 66.1, 128.5, 128.6, 129.2, 129.5, 130.7, 138.0, 156.3, 174.5; anal. calcd for C~19~H~25~NO~4~: C, 68.86; H, 7.60; N, 4.23; found: C, 68.59; H, 7.31; N, 3.93.

**Ethyl (1** ***R*** **\*,2** ***S*** **\*,5** ***R*** **\*,6** ***S*** **\*)-2-(benzyloxycarbonylamino)-5,6-dihydroxycyclooctanecarboxylate ((±)-4)**

![](Beilstein_J_Org_Chem-11-596-i002.jpg)

A colourless oil (*R* ~f~ 0.4, *n*-hexane/EtOAc 1:4); yield: 90%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.26 (t, *J* = 7.15 Hz, 3H, CH~3~), 1.62--1.94 (m, 4H, CH~2~), 1.97--2.28 (m, 4H, CH~2~), 2.77--2.82 (m, 1H, H-1), 3.83--3.89 (m, 2H, H-5 and H-6), 4.02--4.10 (m, 1H, H-2), 4.11--4.19 (m, 2H, OCH~2~), 5.09 (m, 2H, OCH~2~), 5.49 (brs, 1H, N-H), 7.36--7.48 (m, 5H, Ar-H); ^13^C NMR (100 MHz, DMSO) δ 14.8, 21.2, 26.9, 28.5, 29.0, 45.4, 51.6, 60.7, 65.9, 72.3, 72.4, 128.4, 128.5, 129.1, 138.1, 156.3, 174.6; anal. calcd for C~19~H~27~NO~6~: C, 62.45; H, 7.45; N, 3.83; found: C, 62.19; H, 7.10; N, 4.13.

**Ethyl (8** ***R*** **\*,8a** ***S*** **\*)-octahydroindolizine-8-carboxylate ((±)-5)**

![](Beilstein_J_Org_Chem-11-596-i003.jpg)

A yellow oil (*R* ~f~ 0.55, CH~2~Cl~2~/MeOH 95:5); yield: 41%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.27 (t, *J* = 7.15 Hz, 3H, CH~3~), 1.46--1.53 (m, 2H, CH~2~), 1.57--1.92 (m, 5H, CH~2~), 1.99--2.10 (m, 3H, CH~2~), 2.13--2.20 (m, 1H, CH~2~), 2.25--2.31 (m, 1H, H-8), 3.03--3.10 (m, 2H, CH~2~ and H-8a); ^13^C NMR (100 MHz, CDCl~3~) δ 14.6, 20.9, 25.1, 29.5, 30.1, 48.4, 52.6, 54.4, 60.6, 65.6, 174.6; MS (ESI) *m*/*z*: 198.5 \[M + 1\]; anal. calcd for C~11~H~19~NO~2~: C, 66.97; H, 9.71; N, 7.10; found: C, 66.60; H, 10.02; N, 7.39.

**((8** ***R*** **\*,8a** ***S*** **\*)-Octahydroindolizin-8-yl)methanol; ((±)-tashiromine (±)-6)** \[[@R35]--[@R37]\]

![](Beilstein_J_Org_Chem-11-596-i004.jpg)

A yellow oil (*R* ~f~ 0.45, CH~2~Cl~2~/MeOH/NH~4~OH 90:8:2); yield: 48%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.00--1.11 (m, 1H, CH~2~), 1.42--1.53 (m, 2H, CH~2~), 1.58--1.83 (m, 5H, CH~2~), 1.84--1.99 (m, 3H, CH~2~), 2.04--2.11 (m, 1H, CH~2~), 3.03--3.10 (m, 2H, N-CH), 3.41--3.46 (m, 1H, OCH~2~), 3.59--3.64 (m, 1H, OCH~2~); ^13^C NMR (100 MHz, CDCl~3~) δ 21.1, 25.5, 28.0, 29.4, 44.9, 53.1, 54.5, 66.0, 66.9; MS (ESI) *m*/*z*: 156.6 \[M + 1\]; anal. calcd for C~9~H~17~NO: C, 69.63; H, 11.04; N, 9.02; found: C, 69.28; H, 10.70; N, 8.76.

**Ethyl (1** ***S*** **\*,2** ***S*** **\*)-2-(benzyloxycarbonylamino)cyclooct-5-enecarboxylate ((±)-7)**

![](Beilstein_J_Org_Chem-11-596-i005.jpg)

A colourless oil (*R* ~f~ 0.55, *n*-hexane/EtOAc 4:1); yield: 48%; ^1^H NMR (400 MHz, DMSO) δ 1.18 (t, *J* = 7.10 Hz, 3H, CH~3~), 1.55--1.64 (m, 2H, CH~2~), 1.73--1.97 (m, 2H, CH~2~), 2.04--2.19 (m, 2H, CH~2~), 2.33--2.47 (m, 2H, CH~2~), 2.68--2.75 (m, 1H, H-1), 3.88--4.02 (m, 3H, OCH~2~ and H-2), 4.96--5.02 (m, 2H, OCH~2~), 5.53--5.60 (m, 2H, H-5 and H-6), 7.30--7.44 (m, 5H, Ar-H); ^13^C NMR (100 MHz, DMSO) δ 14.8, 24.5, 25.1, 29.2, 33.8, 49.2, 52.1, 60.4, 65.9, 128.0, 128.4, 129.0, 129.1, 130.7, 138.2, 156.9, 174.5; anal. calcd for C~19~H~25~NO4: C, 68.86; H, 7.60; N, 4.23; found: C, 68.57; H, 7.28; N, 3.97.

**Ethyl (8** ***S*** **\*,8a** ***S*** **\*)-octahydroindolizine-8-carboxylate ((±)-9)**

![](Beilstein_J_Org_Chem-11-596-i006.jpg)

A yellow oil (*R* ~f~ 0.45, CH~2~Cl~2~/MeOH 4:1); yield: 40%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.28 (t, *J* = 7.15 Hz, 3H, CH~3~), 1.28--1.33 (m, 1H, CH~2~), 1.42--1.55 (m, 2H, CH~2~), 1.58--1.64 (m, 1H, CH~2~), 1.68--1.86 (m, 3H, CH~2~), 2.02--2.18 (m, 3H, CH~2~), 2.23--2.27 (m, 1H, CH~2~), 2.78--2.81 (m, 1H, H-8), 3.04--3.10 (m, 2H, CH~2~ and H-8a), 4.09--4.17 (m, 2H, OCH~2~); ^13^C NMR (100 MHz, DMSO) δ 15.1, 21.2, 22.6, 26.8, 27.3, 42.0, 53.4, 55.0, 60.5, 64.9, 170.4; MS (ESI) *m*/*z*: 198.7 \[M + 1\]; anal. calcd for C~11~H~19~NO~2~: C, 66.97; H, 9.71; N, 7.10; found: C, 67.28; H, 9.40; N, 6.78.

**((8** ***S*** **\*,8a** ***S*** **\*)-Octahydroindolizin-8-yl)methanol; ((±)-epitashiromine, (±)-10)** \[[@R32],[@R34],[@R39]\]

![](Beilstein_J_Org_Chem-11-596-i007.jpg)

A yellow oil (*R* ~f~ 0.45, CH~2~Cl~2~/MeOH/NH~4~OH 88:8:4); yield: 53%; ^1^H NMR (400 MHz, CDCl~3~) δ 1.56--1.62 (m, 2H, CH~2~), 1.65--1.74 (m, 4H, CH~2~), 1.97--2.12 (m, 5H, CH~2~), 2.20--2.28 (m, 1H, H-8), 2.94--3.00 (m, 1H, CH~2~), 3.08--3.14 (m, 1H, N-CH), 3.70--3.75 (m, 1H, OCH~2~), 4.13--4.19 (m, 1H, OCH~2~); ^13^C NMR (100 MHz, CDCl~3~) δ 21.2, 23.7, 26.3, 30.1, 35.7, 54.0, 54.9, 66.0, 66.8; MS (ESI) *m*/*z*: 156.4 \[M + 1\]; anal. calcd for C~9~H~17~NO: C, 69.63; H, 11.04; N 9.02; found: C, 69.30; H, 10.71; N, 8.79.
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